ArticleMolecular neurobiology2026
CDGSH Iron Sulfur Domain 1 Relieves Neuronal Ferroptosis via Activating AMPK Pathway in Alzheimer's Disease.
Article in Molecular neurobiology, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
9 authors.
Funding
Abstract
CDGSH iron sulfur domain 1 (CISD1) plays important roles in regulating cellular iron and reactive oxygen species (ROS) homeostasis. This study aimed to investigate the effect of CISD1 on neuronal ferroptosis in Alzheimer's disease (AD) cellular models, and the implication of AMPK pathway during this process. CISD1 expression in brain tissues from AD patients and controls was obtained from AlzData public database. HT22 and SH-SY5Y cells were challenged with amyloid-beta (Aβ) to construct AD cellular models. CISD1 or negative-control (NC) overexpression plasmids were transfected into AD cellular models; afterwards, Compound C (an AMPK activator) was added. CISD1 expressions in entorhinal cortex, hippocampus, temporal cortex, and frontal cortex tissues were decreased in AD patients versus controls via AlzData public database analysis. CISD1 expression was also downregulated in AD cellular models versus control cells. Interestingly, cell viability and SLC7A11 and GPX4 expressions were lower, but ROS and Fe
Indexed as
Identifiers
41989641What Socratic holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.